Takhzyro (lanadelumab-fylo)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA. ☐ **URGENT**

MEMBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PHONE NUMBER:	**DATE OF BIRTH:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
PATIENT INSURANCE ID NUMBER:	

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM):** _____ **WEIGHT (LB/KG):** _____ **ALLERGIES:** _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**
NPI NUMBER:	**DEA NUMBER:**
PHONE NUMBER:	**FAX NUMBER:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
REQUESTOR (if different than prescriber)**:**	**OFFICE CONTACT PERSON:**

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**
☐ **NEW THERAPY** ☐ **RENEWAL** DURATION OF THERAPY (SPECIFIC DATES):		**IF RENEWAL:** DATE THERAPY INITIATED:	

Continued on next page

Revision Date: 3/1/2023
CAT0192

Takhzyro (lanadelumab-fylo)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? ☐ YES (if yes, complete below) ☐ NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE)**:**	**DURATION OF THERAPY** (SPECIFY DATES)**:**	**RESPONSE/REASON FOR FAILURE/ALLERGY:**

2. LIST DIAGNOSES:	**ICD-10:**
☐ Hereditary Angioedema(HAE) ☐ Other diagnosis: _____ICD-10 Code(s): _____	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Clinical Information:

<u>Initial Request</u>:

Is the prescriber an allergist or immunologist? ☐ Yes ☐ No

Does patient have a functional C1-inhibitor level equal to or less than 40% of normal? ☐ Yes ☐ No
Please submit lab report.

Does patient have a functional C1-inhibitor level between 40-50%(inclusive) of normal? ☐ Yes ☐ No
Please submit lab report.

Is patient's serum C4 level below normal range? ☐ Yes ☐ No *Please submit lab report.*

Did the patient's first symptoms of angioedema occur at 30 years or younger? ☐ Yes ☐ No
Please submit chart notes.

Does the patient have a family history of hereditary angioedema(HAE)? ☐ Yes ☐ No
Please submit chart notes.

Is the patient's serum C1q level within normal range? ☐ Yes ☐ No
Please submit lab report.

Does the patient have angioedema attacks at least one attack every 12 weeks? ☐ Yes ☐ No
Please submit chart notes.

Has patient been treated and had an inadequate response with attenuated androgens(such as danazol)?
☐ Yes ☐ No *Please submit chart notes.*

Continued on next page

Revision Date: 3/1/2023
CAT0192

Takhzyro (lanadelumab-fylo)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Does patient have at least one contraindication to the use of attenuated androgens(such as danazol)? □ **Yes** □ **No**
Please submit chart notes.

- **Hypersensitivity to the androgen or any component of the formulation;**
- **Undiagnosed genital bleeding;**
- **Pregnancy;**
- **Breastfeeding;**
- **Porphyria;**
- **Impaired hepatic function;**
- **Impaired renal function; and**
- **Impaired cardiac function**

Will patient be using Cinryze(C1 esterase inhibitor) or Haegarda(C1 esterase inhibitor) in combination with Takhzyro? □ **Yes** □ **No**

<u>Renewal Request</u>:
Is patient continuing to demonstrate a positive clinical response? □ **Yes** □ **No** ***Please submit chart notes.***

Will patient be using Cinryze(C1 esterase inhibitor) or Haegarda(C1 esterase inhibitor) in combination with Takhzyro? □ **Yes** □ **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program;
Attn: CP - 4201
P.O. Box 64811
St. Paul, MN 55164-0811

Revision Date: 3/1/2023
CAT0192